GLOW LIFETECH CORP. (9DO) - Net Assets
Based on the latest financial reports, GLOW LIFETECH CORP. (9DO) has net assets worth €2.22 Million EUR (≈ $2.59 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.70 Million ≈ $4.32 Million USD) and total liabilities (€1.48 Million ≈ $1.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 9DO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.22 Million |
| % of Total Assets | 59.93% |
| Annual Growth Rate | -9.22% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 60.17 |
GLOW LIFETECH CORP. - Net Assets Trend (2021–2024)
This chart illustrates how GLOW LIFETECH CORP.'s net assets have evolved over time, based on quarterly financial data. Also explore 9DO current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for GLOW LIFETECH CORP. (2021–2024)
The table below shows the annual net assets of GLOW LIFETECH CORP. from 2021 to 2024. For live valuation and market cap data, see market value of GLOW LIFETECH CORP..
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €2.57 Million ≈ $3.01 Million |
+349.29% |
| 2023-12-31 | €-1.03 Million ≈ $-1.21 Million |
-185.04% |
| 2022-12-31 | €1.21 Million ≈ $1.42 Million |
-64.71% |
| 2021-12-31 | €3.44 Million ≈ $4.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GLOW LIFETECH CORP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 712400100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €21.01 Million | 817.34% |
| Total Equity | €2.57 Million | 100.00% |
GLOW LIFETECH CORP. Competitors by Market Cap
The table below lists competitors of GLOW LIFETECH CORP. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Can Fite Biopharma Ltd
TA:CANF
|
$5.40 Million |
|
Nippon Active Value Fund Plc
LSE:NAVF
|
$5.41 Million |
|
Thunderstruck Resources Ltd
V:AWE
|
$5.41 Million |
|
Algorhythm Holdings, Inc.
NASDAQ:RIME
|
$5.41 Million |
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
$5.40 Million |
|
FATHOM NICKEL INC.
F:6Q5
|
$5.40 Million |
|
CARLSON INV. ZY 13
F:2HB
|
$5.40 Million |
|
Cheer Holding Inc.
NASDAQ:CHR
|
$5.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GLOW LIFETECH CORP.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,031,096 to 2,570,389, a change of 3,601,485.
- Net loss of 2,657,323 reduced equity.
- New share issuances of 2,509,648 increased equity.
- Other factors increased equity by 3,749,160.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-2.66 Million | -103.38% |
| Share Issuances | €2.51 Million | +97.64% |
| Other Changes | €3.75 Million | +145.86% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares GLOW LIFETECH CORP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.42x to 1.68x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.06 | €0.03 | x |
| 2022-12-31 | €0.02 | €0.03 | x |
| 2023-12-31 | €-0.02 | €0.03 | x |
| 2024-12-31 | €0.02 | €0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GLOW LIFETECH CORP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -103.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -317.79%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.45x
- Recent ROE (-103.38%) is above the historical average (-153.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -329.33% | 0.00% | 0.00x | 1.10x | €-11.66 Million |
| 2022 | -181.50% | 0.00% | 0.00x | 1.96x | €-2.32 Million |
| 2023 | 0.00% | -3617.40% | 0.03x | 0.00x | €-1.49 Million |
| 2024 | -103.38% | -317.79% | 0.22x | 1.45x | €-2.91 Million |
Industry Comparison
This section compares GLOW LIFETECH CORP.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $979,793,893
- Average return on equity (ROE) among peers: -18.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GLOW LIFETECH CORP. (9DO) | €2.22 Million | -329.33% | 0.67x | $5.40 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $2.05 Billion |
| BioNTech SE (22UA) | $1.37 Billion | 1.11% | 0.69x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.98 Billion | -7.02% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.67 Billion | -12.59% | 0.28x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About GLOW LIFETECH CORP.
Glow Lifetech Corp., a biotechnology company, focuses on producing nutraceutical and cannabinoid-based products. The company engages in the commercialization of plant-based MyCell technology delivery system; water-soluble ingredients; customized blends; powder-based Capsules, and market-ready products, as well as precision-dosed capsules. It has exclusive North American rights for the production,… Read more